Brian Medel-Lacruz

Brian Medel-Lacruz

Auto-generated profile, based on publicly available information

Brian Medel-Lacruz

Research Programme on Biomedical Informatics, Hospital del Mar Medical Research Institute, Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona, 08003, Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
DADavid Aranda-García
David Aranda-García
TSTomasz Maciej Stepniewski
Tomasz Maciej Stepniewski
MTMariona Torrens-Fontanals
Mariona Torrens-Fontanals
AGAdrian García-Recio
Adrian García-Recio
MLMarta Lopez-Balastegui
Marta Lopez-Balastegui
JSJana Selent
Jana Selent
G protein-coupled receptors (GPCRs) constitute a functionally diverse protein family and are targets for a broad spectrum of pharmaceuticals. Technological progress in X-ray crystallography and cryogenic electron microscopy has enabled extensive, high-resolution structural characterisation of GPCRs in different conformational states. However, as highly dynamic events underlie GPCR signalling, a complete understanding of GPCR functionality requires insights into their conformational dynamics. Here, we present a large dataset of molecular dynamics simulations covering 60% of currently available GPCR structures. Our analysis reveals extensive local “breathing” motions of the receptor on a nano- to microsecond timescale and provides access to numerous previously unexplored receptor conformational states. Furthermore, we reveal that receptor flexibility impacts the shape of allosteric drug binding sites, which frequently adopt partially or completely closed states in the absence of a molecular modulator. We demonstrate that exploring membrane lipid dynamics and their interaction with GPCRs is an efficient approach to expose such hidden allosteric sites and even lateral ligand entrance gateways. The obtained insights and generated dataset on conformations, allosteric sites and lateral entrance gates in GPCRs allows us to better understand the functionality of these receptors and opens new therapeutic avenues for drug-targeting strategies.

20 May 2025 in Science Signaling
Verified
Journal Article
Open access
TRTheo Redfern-Nichols
Theo Redfern-Nichols
SOShannon L. O’bRien
Shannon L. O’bRien
XHXianglin Huang
Xianglin Huang
BMBrian Medel-Lacruz
Brian Medel-Lacruz
DCDavide Calebiro
Davide Calebiro
MMMaria Marti-Solano
Maria Marti-Solano
G protein–coupled receptors (GPCRs) are transmembrane detectors of extracellular signals that activate heterotrimeric G proteins to regulate intracellular responses. Because there are only 16 Gα proteins that can couple to GPCRs, variation in a single Gα can affect the function of numerous receptors. Here, we investigated two mutant forms of Gα s (L388R and E392K) that are associated with pseudohypoparathyroidism type Ic (PHPIc), a maternally inherited rare disease. Gα s is encoded by an imprinted gene, resulting in the mutant form of Gα s being the only version of the protein present in certain tissues, which leads to tissue-specific disease manifestations. By integrating data from three-dimensional structures, GPCR–G protein coupling specificity, transcriptomics, biophysics, and molecular dynamics with systems pharmacology modeling, we identified GPCRs whose signaling could be altered by Gα s mutations in the kidney, a tissue involved in the pathophysiology of PHPIc. Analysis of G protein activation by the parathyroid hormone receptor 1 (PTH1R) revealed that L388R impaired Gα s interaction with the receptor, whereas E392K reduced the receptor-induced activation of heterotrimeric G s . This indicates that different signal transduction steps can be altered by specific Gα s mutants associated with the same disease. These findings highlight the importance of investigating mutation-specific perturbations in GPCR signaling to suggest patient-specific treatment strategies. Furthermore, our methods provide a blueprint for interrogating GPCR signaling diversity in different physiological and pathophysiological contexts.

11 April 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
NNNatasha M. Nesbitt
Natasha M. Nesbitt
GAGian Luca Araldi
Gian Luca Araldi
LPLisa Pennacchia
Lisa Pennacchia
NMNatalia Marchenko
Natalia Marchenko
ZAZahra Assar
Zahra Assar
WBWadie F. Bahou
Wadie F. Bahou
Biliverdin IXβ reductase (BLVRB) is an NADPH-dependent enzyme previously implicated in a redox-regulated mechanism of thrombopoiesis distinct from the thrombopoietin (TPO)/c-MPL axis. Here, we apply computational modeling to inform molecule design, followed by de novo syntheses and screening of unique small molecules retaining the capacity for selective BLVRB inhibition as a novel platelet-enhancing strategy. Two distinct classes of molecules are identified, and NMR spectroscopy and co-crystallization studies confirm binding modes within the BLVRB active site and ring stacking between the nicotinamide moiety of the NADP+ cofactor. A diazabicyclo derivative displaying minimal off-target promiscuity and excellent bioavailability characteristics promotes megakaryocyte speciation in biphenotypic (erythro/megakaryocyte) cellular models and synergizes with TPO-dependent megakaryocyte formation in hematopoietic stem cells. Upon oral delivery into mice, this inhibitor expands platelet recovery in stress thrombopoietic models with no adverse effects. In this work, we identify and validate a cellular redox inhibitor retaining the potential to selectively promote megakaryocytopoiesis and enhance stress-associated platelet formation in vivo distinct from TPO receptor agonists.

21 October 2025 in bioRxiv
Verified
Preprint
Open access
BMBrian Medel
Brian Medel
WZWilliam J. Zamora
William J. Zamora
EHEnric Herrero
Enric Herrero
GKGlen Kellogg
Glen Kellogg
JSJana Selent
Jana Selent
FLF. Javier Luque
F. Javier Luque
Elucidating the correct binding mode of drug-like compounds is crucial to disclose the molecular determinants that underline the recognition by the target protein and estimate the binding affinity, thus guiding the ensuing hit-to-lead optimization. However, the choice of the near-native binding pose in docking experiments remains a major hurdle. Assuming that the hydropathic complementarity principle is the major driving force in ligand-protein recognition, the suitability of simple hydropathicity-based scoring functions to reveal the near-native pose was examined. A benchmarking dataset of 1000 ligand-protein complexes purposely designed to encompass bioactive and decoy poses was used to assess the performance of 3D hydropathicity atomic descriptors derived from empirical and quantum mechanical models. This strategy led to a predictive accuracy of ca. 90% when the non-negligible influence of the conformational stress is also considered. The results reveal the need to leverage nonpolar/polar chemical features for the successful discrimination of the near-native pose.

27 October 2025 in bioRxiv
Verified
Preprint
Open access
BMBrian Medel-Lacruz
Brian Medel-Lacruz
DADavid Aranda-García
David Aranda-García
APAditya Prasad Patra
Aditya Prasad Patra
TSTomasz Stepniewski
Tomasz Stepniewski
AGAdrian García-Recio
Adrian García-Recio
JSJana Selent
Jana Selent
Achieving high-resolution insights into protein dynamics remains a major challenge, particularly for membrane proteins such as G protein–coupled receptors (GPCRs) - a highly dynamic class of cell surface receptors and key drug targets. Here, we present an integrative strategy that bridges computational and experimental biophysical methods for probing protein dynamics. To illustrate its potential, we developed GPCRmd-NMR, a platform that synergistically combines molecular dynamics (MD) simulations with high-resolution nuclear magnetic resonance (NMR) spectroscopy across the 3D GPCRome. The resulting dataset maps over 20 billion NMR signals to more than 7 million conformational snapshots of GPCRs, enabling structure-resolved analysis at an unprecedented scale. Application across multiple GPCRs provides access to previously underexplored functional GPCR dynamics, receptor states, and sites, including microswitches and hidden ligand entrance gateways. Our integrated framework offers a powerful solution to long-standing challenges faced by both experimental and computational researchers. To support broad accessibility, GPCRmd-NMR is available as an open-access, web-based framework equipped with user-friendly analysis tools ( https://www.gpcrmd.org/gpcrmd-nmr-tool ) and is readily applicable to other dynamic protein families beyond GPCRs and other types of biophysical data.